CABLIVI 11 MG — DIN 02496194
CAPLACIZUMAB : 11 MG · SANOFI-AVENTIS CANADA INC · POWDER FOR SOLUTION ; KIT · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is CABLIVI?
CABLIVI 11 MG contains CAPLACIZUMAB : 11 MG. It is listed in the Health Canada Drug Product Database under DIN 02496194, held by SANOFI-AVENTIS CANADA INC, supplied as POWDER FOR SOLUTION ; KIT for INTRAVENOUS ; SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 14-Jan-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is CABLIVI used for?
Cablivi (caplacizumab) is indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PE) and immunosuppressive therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Caplacizumab cost around the world?
Caplacizumab is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory); Italy publishes a ex-factory (classe H). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| United Arab Emirates | public | 1 | 1 |
| Czechia | max producer price (ex-factory) | 1 | 1 |
| Greece | producer price (ex-factory) | 1 | 1 |
| Italy | ex-factory (classe H) | 1 | 1 |
| Luxembourg | reimbursement | 1 | 1 |
| Romania | max producer price | 1 | 1 |
| Saudi Arabia | public | 1 | 1 |
7 pack listings across 7 brand entries and 6 price bases, refreshed 05 Sep 2026. Ranges span every Caplacizumab pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 11 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION ; KIT |
| Route | INTRAVENOUS ; SUBCUTANEOUS |
| Pack configuration (monograph) | Single vial Pack: 1 vial of Cablivi, 1 pre-filled syringe containing 1 mL of sterile water for injection, 1 sterile vial adapter, 1 sterile needle, 2 alcohol swabs. Multi-vial Pack: 7 vials of Cablivi, 7 pre-filled syringes containing 1 mL of sterile water for injection, 7 sterile vial adapters, 7 sterile needles, 14 alcohol swabs. |
| Storage | Use the CABLIVI solution immediately. If not, use CABLIVI within 4 hours after reconstitution when stored in the refrigerator at 2°C to 8°C. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Caplacizumab |
|---|---|
| ATC code | B01AX07 |
| AHFS class | 20:12.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02496194 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2496194 |
| Brand name | CABLIVI |
| Generic / active ingredient | CAPLACIZUMAB : 11 MG |
| Market authorization holder | SANOFI-AVENTIS CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | B01AX07 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01AX |
| Current status | CANCELLED POST MARKET |
| Status date | 14-Jan-2025 |
| Original market date | 2020-09-04 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC B01AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Fondaparinux | ARIXTRA · FONDAPARINUX SODIUM INJECTION | 8 | 4 | Yes |
| Defibrotide | DEFITELIO | 1 | 1 | Yes |
| Caplacizumab | CABLIVI | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B01AF | Apixaban · Edoxaban · Rivaroxaban | 159 | 121 |
| B01AB | Antithrombin · Dalteparin · Danaparoid · Enoxaparin · Heparin · +3 more | 128 | 82 |
| B01AC | Abciximab · Acetylsalicylic Acid · Cangrelor · Clopidogrel · Combinations · +10 more | 158 | 66 |
| B01AA | Acenocoumarol · Warfarin | 62 | 16 |
| B01AE | Argatroban · Bivalirudin · Dabigatran Etexilate · Lepirudin | 18 | 11 |
| B01AD | Alteplase · Ancrod · Anistreplase · Drotrecogin Alfa · Reteplase · +3 more | 22 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.